News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase III
Genmab A/S (GEN.CO) Announces New Phase III Combination Study Of Daratumumab In Multiple Myeloma 4/28/2017
EMD Serono Release: Investigational Cladribine Tablets Data Show Greater Treatment Effect In Relapsing MS Patients At A Higher Risk Of Disease Progression 4/28/2017
eMD Release: Investigational Cladribine Tablets Data Show Greater Treatment Effect In Relapsing MS Patients At A Higher Risk Of Disease Progression 4/28/2017
Medeor Receives FDA Clearance Of IND Application And Special Protocol Assessment For Pivotal Clinical Study Of MDR-101 4/28/2017
Teva Canada (TEVA) Announces Publication Of ARM-TD Study Results In Neurology For The Investigational Use Of Deutetrabenazine In Tardive Dyskinesia 4/27/2017
Some Predict Biogen (BIIB)’s Alzheimer’s Drug Will Fail 4/27/2017
AstraZeneca PLC (AZN)'s Lung Cancer Trial Gets Delayed 4/27/2017
Braeburn Pharma Achieves Primary Endpoint In Pivotal Phase II/III Study Of BB0817, Risperidone 6-Month Implant For Treatment Of Schizophrenia 4/27/2017
Proximagen Limited Release: Midazolam Nasal Spray (Usl261) Phase III Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters 4/27/2017
Novan Presents Safety Data For SB204 Program 4/27/2017
Acceleron Pharma Provides Clinical Development Updates On Luspatercept Program 4/27/2017
Ultragenyx (RARE) Initiates Global Phase III Study Of UX007 In Glut1 DS Patients With Disabling Movement Disorders 4/27/2017
Jazz Pharma (JAZZ) Announces Positive Results From The Phase III TONES 2 Study Of JZP-110 In Narcolepsy Patients With Excessive Sleepiness 4/27/2017
Zogenix (ZGNX) Completes Enrollment In First ZX008 Phase III Clinical Trial In Dravet Syndrome 4/27/2017
Why This SoCal Pharma Could Be Your Best Bet on Alzheimer's 4/26/2017
ARCA biopharma Announces 200th Patient Randomized Into The GENETIC-AF Seamless Design Phase IIB/III Clinical Trial 4/26/2017
New Data At American Academy of Neurology Reinforce Clinical Benefit Of Genentech (RHHBY)'s OCREVUS (Ocrelizumab) For Relapsing And Primary Progressive Multiple Sclerosis 4/26/2017
PhotoCure: Late-Breaking Plenary Presentation At The American Urological Association 2017 Annual Meeting On Blue Light Flexible Cystoscopy With Hexaminolevinulate Phase III Study 4/26/2017
Why Gilead (GILD) Should Pay Close Attention And Maybe Even Fear Allergan (AGN)'s NASH Program 4/25/2017
Can-Fite BioPharma (CFBI)'s Phase III ACRobat Trial In Rheumatoid Arthritis Approved By Institutional Review Board 4/25/2017
Alzheon Scientists Discover Novel Therapeutic Mechanism Of Inhibition Of Formation Of Toxic Beta Amyloid Oligomers, Key Driver Of Alzheimer’s Disease Pathogenesis 4/25/2017
New Data Suggest Positive Effects Of Sanofi Genzyme (SNY)’s Aubagio (Teriflunomide) On Cortical Gray Matter Atrophy 4/25/2017
New Investigational Data On Six-Year Efficacy Of Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) In Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented At American Academy of Neurology 4/25/2017
BeyondSpring Pharmaceuticals Enrolls First U.S. Patient In Phase II/III Clinical Trial Of Plinabulin For Neutropenia Prevention 4/25/2017
ObsEva (OBSV) Initiates Phase III Clinical Program For OBE2109 In Uterine Fibroids 4/25/2017
Shire (SHPG) Initiates Phase III Clinical Trial Program For SHP640 In Infectious Conjunctivitis For Adults And Children 4/25/2017
SillaJen And TRANSGENE (ENX:TNG) Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer 4/25/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
Eli Lilly (LLY) Finally Catches A Break With Encouraging Phase III Breast Cancer Data 4/24/2017
Pierre Fabre Publishes New Data On Dosing Errors With Generic Propranolol For The Treatment Of Infantile Hemangiomas 4/24/2017
Biogen (BIIB) Release: TECFIDERA And TYSABRI Data Demonstrate Improved Outcomes With Early MS Treatment 4/24/2017
Pfizer (PFE) Release: Pivotal Phase III Study Underscores Efficacy Of Zavicefta (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals 4/24/2017
American Regent, Inc. Announces Enrollment Of First Patient In Phase III Trial To Investigate Injectafer (Ferric Carboxymaltose) As Treatment For Heart Failure With Iron Deficiency 4/24/2017
Regeneron (REGN) And Sanofi (SNY) Receive Positive CHMP Opinion For Kevzara (Sarilumab) To Treat Adult Patients With Moderately To Severely Active Rheumatoid Arthritis 4/24/2017
Shionogi Presents New Clinical And Non-Clinical Data On S-033188, An Investigational Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At The 27th European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2017
Ocular Therapeutix (OCUL) To Present Additional Phase III Data And Patient Reported Outcomes Results For DEXTENZA At American Society of Cataract & Refractive Surgery Symposium 4/24/2017
Alder Biopharma Presents Additional Data From Eptinezumab Development Program At 69th Annual American Academy of Neurology Meeting 4/24/2017
Pfizer (PFE) Receives Positive CHMP Opinion For BESPONS (Inotuzumab Ozogamicin) For The Treatment Of Relapsed Or Refractory Acute Lymphoblastic Leukemia 4/24/2017
Adamas Pharma (ADMS) Presents ADS-5102 Pooled Phase III Data Confirming Statistically Significant Reduction In Levodopa-Induced Dyskinesia And OFF Time In People With Parkinson’s Disease 4/24/2017
Biogen (BIIB)'s Newly-Approved Spinraza Successful in Older Children With Spinal Muscular Atrophy 4/24/2017
Sirtex Medical (SRX.AX) Release: SIR-Spheres Y-90 Resin Microspheres Substantially Improves Quality Of Survival In Primary Liver Cancer, New Study Against Standard Treatment Shows 4/24/2017
Lipocine (LPCN) Completes Enrollment In The LPCN 1021 Fixed Dose Clinical Trials 4/24/2017
New Microbiology Data From Paratek Pharma (PRTK) Show Omadacycline Effective Against Most Common Skin Infections And Pathogens, Including MRSA 4/24/2017
Achaogen (AKAO) Unveils Data Highlighting The Effectiveness Of Plazomicin Against MDR Gram-Negative Bacteria At European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) 4/24/2017
New Health Economics Studies Highlight The Potential For Paratek Pharma (PRTK)’ Omadacycline To Provide Cost-Savings Compared To Standard Of Care For The Treatment Of Patients With Acute Bacterial Skin And Skin Structure Infections 4/24/2017
SillaJen And TRANSGENE (ENX:TNG) Announce The Enrollment Of The First European Patient In Multinational Phase III Trial For Pexa-Vec In Advanced Liver Cancer 4/24/2017
Auris Med (EARS) Reports Key Results From Keyzilen AMPACT2 Open-Label Extension Study 4/24/2017
Enanta Pharmaceuticals, Inc. Announces Eight Weeks Of Treatment With AbbVie (ABBV)’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates In Challenging-To-Treat Genotype 3 Chronic HCV Patients 4/21/2017
Incyte (INCY)'s Immuno-Oncology And Targeted Therapy Clinical Portfolio To Be Featured In More Than 15 Abstracts At The 2017 ASCO Annual Meeting 4/21/2017
Gilead (GILD) Presents Data At The International Liver Congress 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread 4/21/2017
Cempra (CEMP) Presents Data At ECCMID Highlighting Need For New CABP Therapies And Activity Of Solithromycin In Key Population Groups 4/21/2017
Basilea (BSLN.SW) Announces Agreement With FDA On Special Protocol Assessments For Antibiotic Ceftobiprole Phase III Clinical Studies In Bloodstream And Skin Infections 4/21/2017
VBL Therapeutics (VBLX) Announces Positive DSMC Review in Phase III GLOBE Trial Investigating VB-111 in rGBM 4/21/2017
Sunovion Announces Positive Results From Pivotal Study Evaluating Novel Drug Candidate Dasotraline In Children With ADHD 4/21/2017
AbbVie (ABBV)'s PARP Inhibitor Fails to Deliver in Two Late-Stage Studies 4/20/2017
Why Former Medivation (MDVN) CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant (AXON) 4/20/2017
Lysogene Announces Selection Of MRI Interventions (MRIC)’ Smartflow Cannula For Phase II/III Clinical Study In MPS IIIA 4/20/2017
Gilead (GILD) Presents Data At The International Liver Congress 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread 4/20/2017
High Response And Remission Rates In Anti-Tnfa Naïve Patients Treated With Qu Biologics’ Novel Immune Therapy For Crohn’s Disease 4/20/2017
Octapharma USA Research Results Presented At HTRS Symposium Targeting Major Challenges Facing Hemophilia Patients 4/20/2017
Enanta Pharmaceuticals, Inc. Announces 99 Percent SVR12 Rate In Chronic HCV Patients With Compensated Cirrhosis Treated With AbbVie (ABBV)'s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P) 4/20/2017
AbbVie (ABBV)'s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate In Chronic Hepatitis C Patients With Compensated Cirrhosis 4/20/2017
Gamida Cell Announces Publication Of Positive Clinical Outcomes From NiCord-Transplanted Patients In The Journal Of Biology Of Blood And Marrow Transplantation 4/20/2017
Sunovion To Present Data On Aptiom (Eslicarbazepine Acetate) At American Academy of Neurology 2017 Annual Meeting 4/19/2017
Boehringer Ingelheim Phase III Study Now Enrolling Patients with Progressive Fibrosing Lung Diseases 4/19/2017
GNT Biotech and Medicals Corporation To Begin Phase III Clinical Trial In Taiwan Of Epigenetic Regulator Chidamide For Late-Stage Breast Cancer 4/19/2017
RedHill Biopharma (RDHL) To Host R&D Day On BEKINDA For Acute Gastroenteritis And IBS-D 4/19/2017
GW Pharma (GWPH) And Its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex (Cannabidiol) Data Released By The American Academy of Neurology 4/19/2017
Argos (ARGS) Reports Interim Results Of The ADAPT Trial And Provides Perspective On Decision To Continue The Trial 4/19/2017
Ultragenyx (RARE), Kyowa Hakko Kirin And Kyowa Kirin International Announce Positive 24-Week Data From Adult Phase II Study Of Burosumab (KRN23) In X-Linked Hypophosphatemia 4/19/2017
Genentech (RHHBY) To Present New Data At AAN Reinforcing Efficacy And Safety Of Newly FDA Approved OCREVUS (Ocrelizumab) In Two Types Of Multiple Sclerosis 4/19/2017
NovoCure Announces Four Presentations On Tumor Treating Fields At American Academy of Neurology Annual Meeting In Boston 4/19/2017
Merck & Co. (MRK) Underscores Continued Commitment To Fighting Infectious Diseases With More Than 25 Data Presentations At ECCMID 2017 4/19/2017
Rigel (RIGL) Submits New Drug Application To FDA For Fostamatinib In Chronic ITP 4/18/2017
Shionogi Presents New Data On Cefiderocol (S-649266), A Siderophore Cephalosporin, And S-033188 A Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza At ECCMID 2017 4/18/2017
FDA Confirms ProMetic BioSciences, Inc.'s PBI-4050 IPF Clinical Trial Design 4/18/2017
How AbbVie (ABBV), Gilead (GILD), Pfizer (PFE) Are All Gaining From Eli Lilly (LLY)'s RA Rejection Pain 4/18/2017
Motif BioSciences, Inc. Announces Positive Results For Iclaprim, In The REVIVE-1 Phase III Study 4/18/2017
Genentech (RHHBY) Shows Off Late-Stage Hemophilia A Data 4/17/2017
NovoCure Release: CNS Oncology Publishes Data Suggesting Survival Benefit Of Optune In Combination With Second Line Chemotherapies After Glioblastoma Recurrence 4/17/2017
FDA Digests Ritter Pharma's Phase II Microbiome Data 4/13/2017
Aerie (AERI) Reports Positive Rocket 4 Six-Month Topline Safety And Efficacy Results For Rhopressatm (Netarsudil Ophthalmic Solution) 0.02% 4/13/2017
Cytel Collaboration Wins Most Innovative Clinical Trial Design At The CARE Awards 2017 4/13/2017
ASIT Biotech Presents Its 2016 Annual Results And Recent Updates In Clinical Developments 4/12/2017
Saniona's Partner, Medix, Obtains Approval To Initiate Phase III Study In Obesity 4/12/2017
3 Drug Giants That Boasts the Best Pipelines 4/11/2017
Biohaven Eyes $100 Million IPO to Bankroll Trials of Shelved AstraZeneca PLC (AZN), Bristol-Myers Squibb (BMY) Drugs 4/11/2017
Tonix Pharma (TNXP) Reports Results From U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting On TNX-102 SL For Posttraumatic Stress Disorder 4/11/2017
Nabriva Announces Enrollment Completion For LEAP 1, A Phase III Clinical Trial Evaluating Lefamulin In Community-Acquired Bacterial Pneumonia 4/11/2017
Genentech (RHHBY)’s Alecensa Superior To Pfizer (PFE)'s Crizotinib In Late-Stage Lung Cancer Trial 4/10/2017
Chugai Pharma's Alecensa Met Its Primary Endpoint In The ALEX Study 4/10/2017
Phase III Study Shows Genentech (RHHBY)’s Alecensa Was Superior To Crizotinib In A Specific Type Of Lung Cancer 4/10/2017
NantCell Announces FDA Grant Of Orphan Drug Designation For The Company’s Ganitumab Monoclonal Antibody Therapy In Ewing Sarcoma 4/10/2017
AbbVie (ABBV) Announces Positive Phase IIb Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women With Uterine Fibroids 4/7/2017
Aurinia (AUPH) Announces Development Plans For Voclosporin In Europe And Japan 4/7/2017
Bellerophon Therapeutics (BLPH) Release: Clinical Data On Inopulse Presented At 37th Annual Meeting For The International Society For Heart And Lung Transplantation (ISHLT) 4/7/2017
Zavante Therapeutics' ZOLYD Met Primary Endpoint In Pivotal ZEUS Study For Treatment Of Complicated Urinary Tract Infections 4/6/2017
Despite a Mixed PhII, Allergan (AGN) Charges Toward a Late-Stage Depression Study for Botox 4/6/2017
Trevena (TRVN) Announces Presentations At The 42nd Annual Regional Anesthesiology And Acute Pain Medicine Meeting 4/6/2017
China FDA Accepts JHL Biotech's First Clinical Trial Application 4/5/2017
Takeda (TKPYY) Completes Enrollment Of More Than 20,000 Children And Adolescents In Global Phase III Trial Of Dengue Vaccine Candidate 4/5/2017
Stock Tanks As NW Bio (NWBO) CTO Pleads Ignorance On Why Study Was Placed On Clinical Hold 4/5/2017
Corbus (CRBP) To Commence Single Phase III Study Of Anabasum For Treatment Of Systemic Sclerosis Following Guidance Received From Successful End-Of-Phase II Meeting With FDA 4/5/2017
OSE Immunotherapeutics Presented New Data At AACR Annual Meeting 2017 On OSE-172 (Effi-DEM), Company's Checkpoint Inhibitor Blocking Suppressive Myeloid Cells And Inducing Antitumoral Potent T Memory Response 4/5/2017
4 Drug Stocks With Major FDA Decisions Coming This Month 4/4/2017
Paratek Pharma (PRTK) Rockets as New Antibiotic Drug Passes Phase III Test 4/4/2017
Wockhardt (WOCKHARDT.BO) Receives Acknowledgement Of Its Breakthrough Superdrug Antibiotic WCK 5222 For Phase III Clinical Trial From US FDA 4/4/2017
Amgen (AMGN) Submits Applications In The US And Europe To Expand Current Indication For XGEVA (denosumab) To Include Patients With Multiple Myeloma 4/4/2017
TherapeuticsMD (TXMD) Presents Positive Phase III Data In Two Presentations For TX-001HR At ENDO 2017 4/4/2017
Peregrine (PPHM) Highlights Clinical Data Presentation At AACR 2017 Annual Meeting Supporting Potential Of Bavituximab To Enhance Anti-Tumor Activity Of Immunotherapy 4/4/2017
Ascendis Showcases New Data On Rare Disease Product Pipeline At ENDO 2017 4/3/2017
Versartis (VSAR) Reports New Data On Long-Acting Somavaratan In Growth Hormone Deficiency At ENDO 2017 4/3/2017
Versartis (VSAR) Announces Three Year Somavaratan Data At ENDO 2017 Showing Safety And Efficacy In Line With Historical U.S. Daily rhGH Data In Pediatric GHD 4/3/2017
Investors Sigh With Relief As Bristol-Myers Squibb (BMY)'s Immunotherapy Combo Extends Survival In Melanoma Patients 4/3/2017
NovoCure Release: Combination Of Optune With Standard Of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates For Newly Diagnosed Glioblastoma Patients 4/3/2017
Bristol-Myers Squibb (BMY) Announces Results From Checkmate -143, A Phase III Study Of Opdivo (Nivolumab) In Patients With Glioblastoma Multiforme 4/3/2017
Bristol-Myers Squibb (BMY) And Incyte (INCY) To Advance The Combination Of Opdivo (Nivolumab) And Epacadostat Into First-Line Registrational Trials 4/3/2017
Asieris Pharma Doses First Patient In China Bladder Cancer Trial 4/3/2017
UroGen Announces Enrollment Of First Patient In Phase III Clinical Trial Of Mitogel For Treatment Of Low-Grade Upper Tract Urothelial Carcinoma 4/3/2017
TetraPhase (TTPH) Completes Enrollment Of IGNITE4 Phase III Clinical Trial Of Eravacycline In Complicated Intra-Abdominal Infections 4/3/2017
Radius Health (RDUS) Release: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies 4/3/2017
Incyte (INCY) And Merck & Co. (MRK) Provide Additional Details On Previously Announced Collaboration Investigating Epacadostat And KEYTRUDA (Pembrolizumab) 3/31/2017
Sunovion To Present Data On LATUDA (Lurasidone HCI) At The 25th European Congress Of Psychiatry 3/31/2017
This Game-Changing Drug Could Be Regeneron (REGN)'s Next Blockbuster 3/30/2017
FDA Grants Priority Review For Amgen (AMGN)'s BLINCYTO (Blinatumomab) Supplemental Biologics License Application 3/30/2017
AstraZeneca PLC (AZN) Release: LYNPARZA (Olaparib) Phase III SOLO-2 Data Demonstrated Progression-Free Survival Benefit In BRCA-Mutated Ovarian Cancer As Maintenance Therapy 3/30/2017
Acasti Pharma Provides Update On CaPre Phase III Development Program 3/30/2017
goBalto, Inc. Releases Industry's First Study Startup Performance Metrics Report 3/30/2017
Acorda (ACOR) Announces Long-Term Safety Data For CVT-301 3/29/2017
Achaogen (AKAO) Announces Data On Epidemiological Trends Of Carbapenem-Resistant Enterobacteriaceae At SHEA Spring 2017 Conference 3/29/2017
Glenmark Pharma Reports Positive Results From A Phase III Trial Of GSP 301, Mometasone/Olopatadine Fixed-Dose Combination Nasal Spray, In Seasonal Allergic Rhinitis 3/29/2017
Intec Pharma Provides Update On Phase III ACCORDANCE Study Of The Accordion Pill Carbidopa/Levodopa In Parkinson's Disease Patients 3/29/2017
Tiny SoCal Pharma Ritter Pharma Hails A Mid-Stage Victory After Changing The Primary Endpoint And Recalculating Data Of Lactose Intolerance Drug 3/29/2017
GW Pharma (GWPH) Announces Epidiolex Receives Orphan Drug Designation From The European Medicines Agency For The Treatment Of Lennox-Gastaut Syndrome 3/29/2017
A Look at Biogen (BIIB)'s Big Bet on the Holy Grail of Science—Alzheimer's 3/29/2017
Vertex (VRTX) Gains Nearly $4 Billion In Market Cap As New Cystic Fibrosis Drug Wows In Two Phase III Studies 3/29/2017
Tesaro (TSRO) Announces Expanded Development Program For Niraparib Focused On The Treatment Of Front-Line Metastatic Ovarian And Lung Cancers And Metastatic Breast Cancer 3/28/2017
Tonix Pharma (TNXP) Enrolls First Participant In Military-Related PTSD Phase III Trial Of FDA Breakthrough Therapy-Designated TNX-102 SL 3/28/2017
ArQule (ARQL)'s Lead Liver Cancer Med Bombs Another Phase III, Stock Tanks 3/27/2017
3 Of The Most Promising Diabetes Meds From 5 Of The Most Innovative Biotechs In The World 3/27/2017
Allergan (AGN) And Paratek Pharma (PRTK) Announce Positive Results From Two Phase III Trials Of Sarecycline For The Treatment Of Moderate To Severe Acne 3/27/2017
Omeros (OMER) To Present Results From Dose-Ranging Stage Of OMS721 Clinical Trial In Atypical Hemolytic Uremic Syndrome At World Congress Of Nephrology 3/27/2017
Foamix Pharma (FOMX) Craters As Acne Drug Flunks Phase III Test 3/27/2017
Infectex Announces Positive Phase IIb-III Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis 3/27/2017
5 Biotechs That Have Major Catalysts Coming in the Next 6 to 9 Months 3/24/2017
Almirall And Sun Pharma (SUNPHARMA.NS) Announce Regulatory Filing Of Tildrakizumab In Europe 3/24/2017
FDA Bestows Breakthrough Tag on Genentech (RHHBY)'s Rituxan for Pemphigus Vulgaris 3/24/2017
Breaking The Cold Chain: New Vaccine Doesn't Need Refrigeration 3/23/2017
The New England Journal of Medicine Publishes Pivotal Phase III Data For CSL Behring's Subcutaneous C1-Esterase Inhibitor In HAE Patients 3/23/2017
Gamida Cell Receives Additional EMA Orphan Drug Designation For Nicord In Haematopoietic Stem Cell Transplantation (HSCT) 3/23/2017
Nanobiotix: The Independent Data Monitoring Committee Recommends The Continuation Of The Ongoing Phase II/IIITrial Of Nbtxr3 In Soft Tissue Sarcoma 3/23/2017
Onxeo To Present Data Supporting Three Key Orphan Oncology Assets At AACR Annual Meeting 3/22/2017
For Sale: Nektar Therapeutics (NKTR) Plans to License Hot New Opioid Drug 3/21/2017
Investors Squeal With Delight as Eli Lilly (LLY)'s Breast Cancer Combo Succeeds in Phase III, Faces Tough Competition from Pfizer (PFE) and Novartis AG (NVS) 3/21/2017
Neurocrine Biosciences (NBIX) Announces American Journal Of Psychiatry Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia 3/21/2017
RedHill Biopharma (RDHL) Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn’s Disease 3/21/2017
Array BioPharma (ARRY) Withdraws Skin Cancer NDA for Binimetinib 3/20/2017
Boehringer Ingelheim Phase III Study Now Enrolling Patients With Progressive Fibrosing Lung Diseases 3/20/2017
Janssen Pharmaceutical Release: New Phase III Study Finds XARELTO To Be Superior To Aspirin For Long-Term Prevention Of Recurrent Blood Clots Without Observing Any Significant Increase In Major Bleeding In Patients With Venous Thromboembolism 3/20/2017
Eli Lilly (LLY) Announces Phase III MONARCH 2 Breast Cancer Study Of Abemaciclib Met Primary Endpoint Of Progression-Free Survival 3/20/2017
Jazz Pharma (JAZZ) Announces Positive Results From The Phase III TONES 3 And TONES 4 Studies Of JZP-110 In Patients With Obstructive Sleep Apnea 3/20/2017
BeyondSpring Pharmaceuticals Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted For Poster Presentation At The 2017 Keystone Symposia In British Columbia 3/20/2017
Palatin Tech (PTN) Receives Notice Of Allowance On Bremelanotide Methods Of Use Patent For Treatment Of Hypoactive Sexual Desire Disorder In Premenopausal Women 3/20/2017
Humacyte Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Expedited Review Designation For HUMACYL In Vascular Access For Hemodialysis 3/20/2017
Resverlogix (RVX.TO) Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase III Study Of Apabetalone And Provides An Update On Corporate Activities 3/17/2017
Eli Lilly (LLY) Release: First Dedicated Outcome Trials Of Empagliflozin In Chronic Heart Failure Initiated 3/17/2017
Agile Therapeutics, Inc. Announces A Poster Presentation Of Its SECURE Phase III Study At The Contraceptive Technology 2017 Conference 3/17/2017
Bristol-Myers Squibb (BMY) And Pfizer (PFE) Present Large Real-World Observational Analysis Of The Effectiveness And Safety Of Direct Oral Anticoagulants Compared To Warfarin In Patients With Non-Valvular Atrial Fibrillation 3/17/2017
Alkermes (ALKS) Initiates Phase III Gastrointestinal Tolerability Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 3/16/2017
Jazz Pharma (JAZZ) Announces First Patient Enrolled In Phase III Clinical Study Evaluating JZP-258 For The Treatment Of Cataplexy And Excessive Daytime Sleepiness In Narcolepsy 3/16/2017
PHARNEXT Announces Initiation Of Phase III Extension Study PLEO-CMT-FU Of PXT3003 For Treatment Of Charcot-Marie-Tooth Disease Type 1A 3/16/2017
AstraZeneca PLC (AZN) Steals Tesaro (TSRO)'s PARP Thunder With Phase III Ovarian Cancer Data 3/16/2017
Vtesse Completes Enrollment Of Phase IIb/III Pivotal Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 3/15/2017
New Publication Describes Positive Patient Experience In Study Of Ocular Therapeutix (OCUL)’s DEXTENZA Following Cataract Surgery 3/15/2017
FDA Demands Karyopharm (KPTI) Stop Enrollment of All Selinexor Trials 3/14/2017
LSK BioPharma Announces Enrollment Of First Patient In Phase III Apatinib Trial In Gastric Cancer 3/14/2017
AbbVie (ABBV) Granted Priority Review In Japan For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C 3/14/2017
One Death in the HAVEN 1 Trial Complicates Roche (RHHBY)’s Entry into the Hemophilia A Market 3/13/2017
Investors Anxiously Await for Amgen (AMGN)'s 27,500-Patient Heart Trial Data This Week 3/13/2017
Amgen (AMGN) Release: Repatha (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase III Study 3/13/2017
Pfizer (PFE) And Merck & Co. (MRK) Go For An Even Longer Throw Of The Javelin 3/10/2017
DBV Tech Announces Completion Of Enrollment Of The REALISE Study In Peanut Allergic Children 3/10/2017
TiGenix Announces Positive Topline Week-104 Data For Cx601 ADMIRE-CD Trial 3/9/2017
Ipsen (IPN.PA) Announces Data Presentations Of Lanreotide (Somatuline Autogel), Telotristat Ethyl And The Investigational Compound 177Lu-OPS201 At The European Neuroendocrine Tumor Society (ENETS) 2017 Conference 3/9/2017
Aurinia (AUPH) Reports Fourth Quarter And Full Year 2016 Financial Results And Recent Operational Highlights 3/9/2017
Allergan (AGN) Release: FDA Accepts Supplemental New Drug Application (sNDA) For VRAYLAR (cariprazine) 3/8/2017
Achieve Life Science And OncoGenex (OGXI) Announce Cytisine Symposium At The Annual Society For Research In Nicotine And Tobacco Conference ("SRNT") 3/8/2017
DalCor's Phase III Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule 3/7/2017
Akcea Therapeutics And Ionis Pharma (IONS) Announce Positive Results From Pivotal Study Of Volanesorsen In Patients With Familial Chylomicronemia Syndrome (FCS) 3/7/2017
Shire (SHPG) Release: CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative To Patients' Previous Immunoglobulin Therapy 3/7/2017
TiGenix Receives Positive Feedback From The FDA On Cx601 Global Phase III Trial Protocol 3/7/2017
ObsEva (OBSV) Starts Phase III Clinical Program For Nolasiban In ART 3/7/2017
Not Giving Up: Roche (RHHBY) To Start New Phase III Tests With Once-Failed Alzheimer's Drug 3/7/2017
Revance (RVNC) Completes Enrollment In Phase III Pivotal Trials Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines 3/7/2017
TG Therapeutics (TGTX) Rockets After Leukemia Drug Clears Hurdle in Late-Stage Study 3/6/2017
ImmunoCellular Therapeutics (IMUC) Provides Update On ICT-107 Phase III Glioblastoma Trial And Announces Advances In Stem-To-T-Cell Research Program 3/6/2017
Regeneron (REGN) And Sanofi (SNY) Announce Presentation Of Positive Data From Long-Term Pivotal Phase III CHRONOS Study Of DUPIXENT (Dupilumab) In Moderate-To-Severe Atopic Dermatitis 3/6/2017
Daiichi Sankyo Initiates ENTRUST-AF PCI Study Investigating Once-Daily SAVAYSA (Edoxaban) In Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention With Stenting 3/6/2017
Bristol-Myers Squibb (BMY) And Pfizer (PFE) To Present New Analyses Of Eliquis (Apixaban) Clinical And Real-World Data At American College of Cardiology 2017 Scientific Session 3/6/2017
ARCA biopharma Announces 175th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial 3/6/2017